RBX7455 & Clostridioides difficile infection (CDI) (recurrent)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The non-randomized clinical phase I treatment trial, identified as NCT02981316 - RBX7455 & Clostridioides difficile infection (CDI) (recurrent), demonstrated that three different dosing regimens of RBX7455 were both safe and effective in preventing Clostridioides difficile infection (CDI) (recurrent). The microbiomes of the responders showed a convergence towards the composition of RBX7455. These findings support the continued clinical evaluation of RBX7455.
Khanna et al. 2021 Clin Infect Dis 73(7): e1613-e1620

see also:
[Clostridioides difficile infection (CDI) (recurrent) & Drugs/Treatments](…

First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
Khanna et al. 2021 Clin Infect Dis 73(7): e1613-e1620

11/5/2026